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Abstract
Background: Granulocyte colony-stimulating factor (G-CSF)-producing esophageal squamous cell carcinoma (ESCC)
has been considered to have a poor prognosis. We successfully treated a case of G-CSF-producing ESCC in a 92-year-
old woman.
Case presentation: A 92-year-old woman was admitted to our hospital with the complaints of choking while
swallowing and dysphagia. Esophagogastroduodenoscopy and contrast-enhanced computed tomography revealed a
type 2 esophageal cancer located 26–35 cm from the dental arch, with no distant metastasis. The patient was
diagnosed with G-CSF-producing ESCC based on remarkable leukocytosis and high G-CSF levels. The patient
underwent radical subtotal esophagectomy. Subsequently, the level of neutrophils (from 23,500/μL to 5000/μL) and
the level of G-CSF (from 131 to <19.5 pg/mL) decreased significantly. Immunohistochemistry analysis of the resected
tissue specimen showed positive staining for G-CSF in the cytoplasm of the tumor cells. Although the patient
developed aspiration pneumonitis, after antibiotic treatment, she promptly recovered and was discharged.
Conclusions: Herein, we describe a case of successfully treated G-CSF-producing ESCC in a 92-year-old woman. Precise
detection and safely performed immediate radical operation are considered essential to achieve a good clinical course.
Keywords: Granulocyte colony-stimulating factor, Esophageal squamous cell carcinoma, Granulocyte colony-
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Background
In addition to the mass tumor effects, granulocyte colony-
stimulating factor (G-CSF)-producing tumors display add-
itional signs and symptoms of inflammation caused by G-
CSF-producing malignant cells [1]. There have been a
relatively high number of reports on G-CSF-producing
lung carcinoma; however, reports on G-CSF-producing
esophageal squamous cell carcinoma (ESCC) have been
scarce.
With the aging of the population, the number of oldest
old patients with cancer comorbidities has been
increasing [2]. Therefore, effort should be made to deter-
mine the effectiveness of each treatment plan.
We report a very rare case of a 92-year-old woman
who was promptly diagnosed with G-CSF-producing
ESCC and successfully underwent surgical treatment.
Case presentation
A 92-year-old woman had a major complaint of choking
when swallowing or dysphagia. The patient had been
healthy and had no particular medical history besides
cataract surgery. She had no history of oral medications,
smoking, or alcohol. Another physician had previously
attended to her was complaint of choking when swallow-
ing. A narrowing of the lumen of the intrathoracic esopha-
gus was detected by esophagogastroduodenoscopy, and
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the patient was referred to our hospital for detailed
examination.
On admission, abnormal symptoms such as fever,
anemia, or jaundice were not detected and the perform-
ance status was good (score 0 according to the Eastern
Cooperative Oncology Group). Laboratory data on ad-
mission showed remarkable leukocytosis (leukocytes
23,500/μL, neutrophils 86.1 %, and no blast cells) and
slight decrease in the serum albumin (3.5 g/dL) and C-
reactive protein (CRP) levels (1.5 mg/dL). The levels of
tumor markers, squamous cell carcinoma antigen
(SCC-A), and p53 antibody were high (SCC-A, 3.4 ng/
mL; p53, 22.2 U/mL). The respiratory functions and
electrocardiograms were within normal ranges. How-
ever, the renal function was a slight concern.
Esophagogastroduodenoscopy revealed a type 2, cir-
cumferential cancer of the esophagus, approximately
at 26–35 cm from the dental arch (Fig. 1), and the
biopsy showed SCC. Contrast-enhanced computed
tomography of the chest and abdomen demonstrated
circumferential thickening of the wall and narrowing
of the lumen of the middle and lower intrathoracic
esophagus, and small lymph nodes were detected be-
tween the lower mediastinum and paracardiac area.
Pleural effusion and ascites or distant metastases were
not detected (Fig. 2).
Based on these findings, the patient was diagnosed
with T3N0M0, stage IIA (according to the Union for
International Cancer Control TNM classification of
malignant tumors, 7th edition) ESCC. Furthermore, the
laboratory data suggested G-CSF-producing carcinoma
with serum G-CSF levels of 131 pg/mL.
Despite her age, the patient had no comorbidities, and
most importantly, she consented to a surgical operation.
Therefore, we planned to perform esophagectomy. In
Japan, the standard treatment for stage IIA esophageal
carcinoma is subtotal esophagectomy with three-field
lymph node dissection following preoperative chemo-
therapy [3]. However, considering the age disadvantage,
multimodal management of disease with chemotherapy
or radiotherapy was not performed.
In fact, the subtotal esophagectomy under the right
thoracolaparotomy, right lower partial lobectomy, two-
field lymph node dissection (instead of three-field), pos-
terior mediastinal route gastric tube reconstruction, and
intra-pleural anastomosis were successfully performed.
The operation lasted 4 h and 15 min, and the blood loss
was 50 mL. The tumor and the right lobe of the lung
were attached; therefore, they were resected en bloc be-
cause the tumor was considered infiltrative.
Histopathological examination of the resected specimen
revealed that the primary lesion sized 92 × 54 mm was a
moderately differentiated squamous cell carcinoma with
two lymph node metastases, and it was diagnosed as a stage
III tumor (according to the Union for International Cancer
Control TNM classification) (Fig. 3a, b). Immunohisto-
chemistry of the resected tissue specimen stained positive
for G-CSF in the cytoplasm of the tumor cells (Fig. 3c).
Fig. 1 Esophagogastroduodenoscopy findings. Esophagogastroduodenoscopy revealed a type 2, circumferential esophageal cancer of the
esophagus approximately at 26–35 cm from the dental arch
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After the operation, the patient developed aspiration
pneumonitis; however, she promptly recovered with the
administration of antibiotics. Three weeks after the oper-
ation, the leukocyte counts decreased to 5000/μL and
the G-CSF levels to <19.5 pg/mL. Thereafter, the patient
exhibited a good clinical course and she was discharged
on the 29th postoperative day.
The patient had neutrophilia without any signs of in-
fection or myeloblast genesis before the operation. After
esophagectomy, the number of leukocytes and the level
of G-CSF had decreased significantly and the presence
of G-CSF was confirmed pathologically. Therefore, the
patient was definitively confirmed to have a G-CSF-
producing tumor.
There have not been any complaints or recurrence, and
the patient has remained disease-free from 18 months
after the operation until the present day.
Discussion
Robinson first described a G-CSF-producing tumor in
1974 [1], and the number of such cases has been in-
creasing in the recent years. The primary sites of G-CSF
cases have been reported as the lung, urinary tract, or
the stomach [4–6]; however, reports of G-CSF-
producing esophageal carcinoma have been scarce.
G-CSF is a hematopoietic factor produced by the
endothelium, macrophages/monocytes, and fibroblasts.
It stimulates the bone marrow to produce granulocytes
from stem cells and release neutrophils into the blood-
stream [7]. It is also produced by the malignant cancer
cells. An excess amount of aberrant production causes
an inflammatory response such as fever and positive
CRP, a kind of leukemoid reaction (leukocytosis >50,000
leukocytes/μL), and paraneoplastic syndrome in clinical
oncology. A recombinant form of G-CSF is currently
Fig. 2 Contrast-enhanced computed tomography findings. Contrast-
enhanced computed tomography demonstrated circumferential
thickening of the wall of the middle and lower
intrathoracic esophagus
Fig. 3 Pathological findings. a Macroscopic examination of the primary lesion of the resected esophagus sized 92 × 54 mm. b Hematoxylin and
eosin stains of the resected tissue specimen revealed moderately differentiated squamous cell carcinoma. c Immunohistochemistry of the
resected tissue specimen showed positive staining for granulocyte colony-stimulating factor (G-CSF) in the cytoplasm of the tumor cells
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History of cancer Treatment Prognosis
1 Watanabe 81 Woman 22,100 1175 Mt Unknown Unknown Lung (simultaneous) BSC 12 days Dead
2 Ichiishi 66 Man 33,900 Unknown Lt Unknown G2-3 Stomach
(simultaneous)
BSC 2 months Dead
3 Matsumoto 66 Man 41,500 154 Lt IV G2 None Resection + CRT l6 months Dead
4 Kato 54 Man 16,900 150 Lt IV G2 None Chemotherapy 3 months Deed
5 Komatsu 73 Man 45,710 231 AeLtG IIB G2 Stomach
(simultaneous)
Resection 19 months Alive
6 Nakata 56 Man 24,300 78 Lt IIB G2 None Resection + CRT 10 months Alive
7 Mimatsu 69 Man 19,600 113 Mt IV G3 None Radiation 7 months Dead
8 Tanabe 76 Man 24,260 134 LtAeG Unknown G2 None Resection, CRT 10 months Dead





10 Shimakawa 73 Man Unknown 41 Unknown Unknown G2 Unknown Chemotherapy 2 months Dead
11 Shimakawa 70 Man 16,700 254 Lt IIIB G2 None NAC + resection 12 months Dead
12 Our case 91 Woman 23,500 131 LtMt IIIA G2 None Resection 18 months Alive












used to prevent infections after chemotherapy or radio-
logical therapy, which causes myelosuppression and
neutropenia.
The diagnostic criteria for G-CSF-producing tumors
include (1) a marked increase in the leukocyte counts,
(2) elevated G-CSF activity, (3) a decrease in leukocyte
counts following tumor resection, and (4) the verifica-
tion of G-CSF production in the tumor [1]. Because all
four criteria were fulfilled, we diagnosed the patient with
G-CSF-producing ESCC.
Esophageal carcinoma is a disease with a poor progno-
sis [8]. Furthermore, the prognosis of G-CSF-producing
ESCC is considered even poorer (Table 1) [9–18]. All of
the cases have been found at rather advanced stage, in
12 cases (including our case), and 9 cases were poor
prognosis. The reason might include (1) G-CSF per se
having a capacity to expand tumor growth in an auto-
crine manner, (2) acute renal failure or hyperuricemia
(so-called tumor lysis syndrome) by cytolysis of in-
creased neutrophils after chemotherapy, (3) thrombosis
by platelet aggregation by G-CSF [19]. The surviving
three patients had undergone tumor resection. Further-
more, among the poor prognosis group, the survival
period of excised cases was estimated to be longer than
that of non-excised cases. From the above, in cases of
the G-CSF-producing ESCC, if possible, the complete
tumor resection is considered to be important. Since the
prognosis of this disease is much poor, if possible, sur-
gery as well, multimodal therapy that combines radio-
therapy and/or chemotherapy is considered preferable.
According to Table 1, G-CSF-producing ESCC was
male-dominated (83.3 %) and the average age of the 12
patients was 67 years old. These findings were consid-
ered to overlap with the population of normal ESCC.
Association between leukocyte value, serum G-CSF
value, tumor location, tumor stage, histologic grade, and
prognosis was not clear. In addition, in one third in
these 12 cases, a merger of other organs’ tumor was ob-
served. It is suggested that the characteristic of G-CSF,
which was mentioned above, might have influence on
tumor growth [19].
In addition, with the aging of the population, the
chances that we encounter the oldest old patients are in-
creasing [8]. The appropriate evaluation of overall condi-
tions and the selection of operative method are critical.
The operative reports of the elderly are few, and among
those cases, the cytoreductive (limited) operations were
often chosen [20–22] because of the increase of compli-
cations after the operation.
In the present case, the oldest old patient has been
alive with a good condition after the operation. In order
to improve the quality of life of the oldest old patients,
the practical consideration for esophageal carcinoma
should be the individualization of therapeutic protocols,
tailoring the extent of resection and inclusion or exclu-
sion of preoperative and postoperative procedures. A
curative resection with relatively minimal invasion ap-
pears to be mandatory for better prognosis with minimal
morbidity and mortality in elderly patients.
Conclusions
We described a case of successfully treated G-CSF-
producing esophageal squamous cell carcinoma in a 92-
year-old woman. We assessed the patient’s will and over-
all condition and chose the best operative method of
radical subtotal esophagectomy and could achieve a
good clinical course.
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